Year All2024202320222021202020192018201720162014201320112010 March 19, 2018 Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018 March 12, 2018 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results March 7, 2018 Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March January 4, 2018 Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity November 14, 2017 Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results October 31, 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome October 10, 2017 Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares October 4, 2017 Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering August 1, 2017 Rhythm Expands Executive Leadership Team June 27, 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
March 19, 2018 Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
January 4, 2018 Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
October 31, 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
October 10, 2017 Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 27, 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
